YAP1 Is a Prognostic Marker and Its Inhibition Reduces Tumor Progression in Adrenocortical Tumors
YAP1 is a potential novel prognostic marker in patients with ACC. Its deregulation contributes to adrenocortical tumorigenesis partially through crosstalk between Hippo/YAP1 and Wnt/β-catenin pathways. YAP1 inhibition is a new antitumor target.
Authors
- Sílvia Regina Brandalise (ORCID: https://orcid.org/0000-0003-3696-9852)
- José Andrés Yunes (ORCID: https://orcid.org/0000-0002-1316-3525)
- Candy Christie Bellido More
- Margaret de Castro (ORCID: https://orcid.org/0000-0003-4932-4623)
- Sonir Roberto Rauber Antonini (ORCID: https://orcid.org/0000-0003-4778-8803)
- Thais Junqueira
- Ana Carolina Bueno (ORCID: https://orcid.org/0000-0001-9043-9831)
- Izilda Aparecida Cardinalli (ORCID: https://orcid.org/0000-0002-7329-3970)
- César Alexander Ortiz Rojas (ORCID: https://orcid.org/0000-0003-3420-803X)
- Fernando Silva Ramalho (ORCID: https://orcid.org/0000-0002-7529-466X)
- Mônica Freire Stecchini (ORCID: https://orcid.org/0000-0003-2420-270X)
- Carlos Alberto Scrideli (ORCID: https://orcid.org/0000-0001-6618-789X)
Institutions
- Universidade de Ribeirão Preto (BR)
- Universidade de São Paulo (BR)
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Centro Infantil Boldrini (BR)
- Clinics Hospital of Ribeirão Preto (BR)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1210/clinem/dgaf013
- Citations
- 3
- Primary Topic
- Adrenal and Paraganglionic Tumors
- Type
- article
- Field-Weighted Citation Impact
- 6.02